Martin Shkreli (Shutterstock)

Mar­tin Shkre­li con­tin­ued to or­ches­trate an­ti-com­pet­i­tive schemes for Dara­prim be­hind bars — FTC

Mar­tin Shkre­li didn’t just blog, read up on drug de­vel­op­ment news and run his biotech busi­ness with a con­tra­band cell phone in prison. Ac­cord­ing to the FTC, he was al­so co­or­di­nat­ing the an­ti­com­pet­i­tive scheme to shield Dara­prim — the drug at the cen­ter of a price-goug­ing con­tro­ver­sy that earned him the “Phar­ma Bro” nick­name — from gener­ic ri­vals.

Back in Jan­u­ary the FTC, to­geth­er with New York’s at­tor­ney gen­er­al, launched a fed­er­al law­suit against Shkre­li, who’s now serv­ing a 7-year sen­tence for de­fraud­ing in­vestors in his hedge fund, al­leg­ing that he ef­fec­tive­ly cre­at­ed a drug mo­nop­oly. While Shkre­li’s no­to­ri­ous move to raise the per tablet price of Dara­prim from $17.50 to $750 was per­fect­ly le­gal, the tac­tics he al­leged­ly de­ployed to box out com­peti­tors weren’t.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.